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Colorectal cancer is the third most common type of cancer and the major cause of the death throughout 
the world. Widely known, carcinoembryonic antigen (CEA) is an important tumour marker responsible 
for clinical diagnosis of 95% of all colon tumors1. The discovery of novel non-invasive biomarkers, as 
CEA, and its fast determination at low cost is presently required, to enable its use over wide screening 
programs and applications in point-of-care context, and, thus, its monitoring quite early. 
As a novel approach, this work proposes a novel support with molecular imprinted polymer (MIP) for 
CEA cancer biomarker based on carbon ink matrix linked by sol-gel chemistry on top of conductive 
glass covered by fluorine-doped tin oxide (FTO glass). In brief, the electrical biosensor was tailored on 
top of a disposable conductive glass electrode, following a bottom-up approach. The several stages of 
this process included the chemical modification of a homemade carbon ink layer and the assembly of a 
MIP or non-imprinted polymer (NIP) layer.  
The analytical performance of the obtained devices was followed by electrochemical impedance 
spectroscopy (EIS) and cyclic voltammetry (CV). Chemical modifications of the surface were 
characterized using Fourier Transform Infrared (FTIR), and Raman spectroscopy with confocal 
microscopy. Overall, the MIP/FTO glass-based device displayed linear responses to CEA in EIS assays 
from 2.5×10-3 µg.mL-1 to 1.25 µg.mL-1 in PBS buffer, with detection limits of 2.5×10-3 µg.mL-1. 
Successful detection of CEA was, also, achieved in spiked samples of fetal bovine serum. 
In conclusion, the devices developed are a promising tool for the monitoring of CEA in a point-of-care 
applications, due to its detection capability below the normal physiological levels expected for this 
cancer biomarker, simplicity of manufacture, low-cost and good sensitivity and selectivity. 
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